10:43 AM EDT, 07/16/2025 (MT Newswires) -- MBX Biosciences' ( MBX ) hypoparathyroidism drug, canvuparatide, is a "key catalyst" for the company as its potentially favorable efficacy to current treatments could be a $2 billion global peak sales opportunity, said Oppenheimer said in a Wednesday note.

Oppenheimer said its enthusiasm for MBX Biosciences ( MBX ) stems from the company's precision endocrine peptide platform and its potential to "redefine standards" in endocrine and metabolic disease treatment.

The firm initiated coverage on MBX Biosciences ( MBX ) with an outperform rating and a $38 price target.

Price: 12.40, Change: -1.00, Percent Change: -7.46